Mitchell & Pahl Private Wealth LLC Has $632,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Mitchell & Pahl Private Wealth LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,878 shares of the company’s stock after selling 163 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in Zoetis were worth $632,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ZTS. AE Wealth Management LLC raised its stake in shares of Zoetis by 9.5% in the 2nd quarter. AE Wealth Management LLC now owns 1,988 shares of the company’s stock valued at $345,000 after acquiring an additional 172 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Zoetis by 32.4% during the second quarter. Pacer Advisors Inc. now owns 40,374 shares of the company’s stock valued at $6,999,000 after purchasing an additional 9,872 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Zoetis by 2.5% in the second quarter. ProShare Advisors LLC now owns 109,521 shares of the company’s stock valued at $18,987,000 after purchasing an additional 2,633 shares during the period. Frank Rimerman Advisors LLC lifted its stake in shares of Zoetis by 46,636.8% in the second quarter. Frank Rimerman Advisors LLC now owns 8,880 shares of the company’s stock worth $1,539,000 after buying an additional 8,861 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC boosted its holdings in shares of Zoetis by 12.7% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 4,366 shares of the company’s stock worth $757,000 after buying an additional 493 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $166.01 on Tuesday. The stock’s 50 day simple moving average is $170.93 and its 200-day simple moving average is $180.01. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market cap of $74.90 billion, a PE ratio of 31.20, a P/E/G ratio of 2.55 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the company earned $1.36 earnings per share. The business’s revenue was up 11.6% compared to the same quarter last year. Sell-side analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is 32.52%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Finally, Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.